AdvanceMarketAnalytics, a global market research and consulting organization, have released a new study titled "Antidiabetic Drug market - Global outlook to 2026".
Industries constant focus on reducing the operational cost and increased attention on core business, and need to improve scalability are expected to shape the Global Antidiabetic Drug market to grow at a CAGR of 7.35% to aggregate USD110896.57 Million by 2026.

The Drug Type, such as Generic, is boosting the Antidiabetic Drug market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

The Route of Administration, such as Oral (eg. oral hypoglycemic), is boosting the Antidiabetic Drug market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

The Distribution Channel, such as Hospital Pharmacies, is boosting the Antidiabetic Drug market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

The Drug Class, such as Biguanides (Metformin), is boosting the Antidiabetic Drug market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

According to Analyst at AMA Research, the Global Antidiabetic Drug market will experience significant growth during the forecast period due to potential opportunities lying in the market such as . Some of the important driving forces are “Increasing Prevalence of Diabetes Population among Patients, Rising Disposable Income and Sedentary Lifestyle of Consumers and Increasing Government Support and Awareness Related to Diabetes”.
 

According to the International Diabetes Federation estimates, the prevalence of diabetes is anticipated to escalate from 366 million in 2011 to 552 million by 2030. Statistically, approximately 80% to 90% of the patients diagnosed with diabetes are also treated with obesity. Moreover, Type I and type II diabetes is expected to propel the demand for oral hypoglycemic drugs as it is a proven diabetes controller among patients globally. Further, the rising investments on healthcare facilities have led the pharmaceutical industry to experiment with more pipeline drugs for diabetes which in turn is fostering the global anti diabetes drugs market.

The report provides an in-depth analysis and forecast about the industry covering the following key features:
o Industry outlook including current and future market trends, drivers, restraints, and emerging technologies
o Analyses the Global Antidiabetic Drug market by Type (Type II Diabetes) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
o Analyzes the top 10 players in terms of market reach, business strategy, and business focus
o Provides stakeholders’ insights and key trends (current and future) of the market